Old Testimony Spurs New Claims In Amgen-Ariad Suit

Law360, New York (February 4, 2008, 12:00 AM EST) -- A federal judge has cleared the way for Amgen Inc. to add new claims of inequitable conduct to the declaratory judgment suit against Ariad Pharmaceuticals Inc. over its arthritis treatment patent.

Judge Mary Pat Thynge on Thursday allowed Amgen to raise fresh allegations that Ariad failed to point out an expert deposition during the reexamination of its patent by the U.S. Patent and Trademark Office and concealed information on patent validity.

In the lawsuit, filed in April in the U.S. District Court for the District of...
To view the full article, register now.